Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) Equity Average (2018 - 2025)

Sutro Biopharma (STRO) has disclosed Equity Average for 8 consecutive years, with -$109.9 million as the latest value for Q4 2025.

  • Quarterly Equity Average fell 241.01% to -$109.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$109.9 million through Dec 2025, down 241.01% year-over-year, with the annual reading at -$43.9 million for FY2025, 145.23% down from the prior year.
  • Equity Average hit -$109.9 million in Q4 2025 for Sutro Biopharma, down from -$59.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $319.7 million in Q1 2021 to a low of -$109.9 million in Q4 2025.
  • Historically, Equity Average has averaged $149.5 million across 5 years, with a median of $151.8 million in 2023.
  • Biggest five-year swings in Equity Average: skyrocketed 255.46% in 2021 and later plummeted 241.01% in 2025.
  • Year by year, Equity Average stood at $268.1 million in 2021, then fell by 16.67% to $223.4 million in 2022, then plummeted by 41.34% to $131.0 million in 2023, then plummeted by 40.54% to $77.9 million in 2024, then tumbled by 241.01% to -$109.9 million in 2025.
  • Business Quant data shows Equity Average for STRO at -$109.9 million in Q4 2025, -$59.7 million in Q3 2025, and -$29.0 million in Q2 2025.